Trial Profile
An Open-Label Controlled Phase I/III Study to Evaluate the Safety and Immunogenicity of Pneumococcal 7-Valent Conjugate Vaccine [DIPHTHERIA CRM197 PROTEIN] (PrevenarTM) in Healthy Infants.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Apr 2013
Price :
$35
*
At a glance
- Drugs Pneumococcal 7-valent CRM197 vaccine conjugate (Primary) ; DTaP vaccine
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Sponsors Wyeth
- 18 Jul 2007 New trial record.